newsfilter
← Earnings
Earnings Releases·

Seer, Inc. — Third Quarter 2026 Earnings Summary

  • Revenue decreased 3% year-over-year to $4.0 million for Q3 2026, while operating expenses fell 23% to $16.5 million, resulting in a narrowed net loss of $13.7 million compared to $18.2 million in the prior-year period.
  • Full-year 2026 revenue guidance was lowered to $13.5–$14.5 million from the previous $16–$18 million range due to extended sales cycles and funding pressures, though management cites sufficient capital to reach cash flow breakeven.
  • The company repurchased approximately 13.5 million shares for $25 million through September 30, 2026, and confirmed it will remain an independent public entity following a board review.
  • The ITC investigation staff recommended full exclusion and cease-and-desist orders after Nanomics Biotechnology withdrew its defense, with a final determination expected by year-end.
Company
SEER INC
Sector
Healthcare
Industry
Biotechnology